June 5, 2006 – The FDA gave its OK for multiple sclerosis drug Tysabri from Biogen Idec and Elan to re-enter the marketplace; at ASCO, the star has been the GlaxoSmithKline drug, Tykerb, a breast cancer therapy; Bayer and Onyx reported that Nexavar, their kidney cancer drug, showed only a modest improvement in survival; Sutent from Pfizer and Temsiroliumus from Wyeth both produced better data; Pfizer also released positive data from a trial that pitted Sutent against lung cancer; Amgen showed good data from a colorectal cancer drug; Abraxis said Abraxane provoked a response in lung cancer patients; Oncophage from Antigenics failed to meet its endpoint in a melanoma trial; Merck will file for approval of a diabetes drug earlier than expected; Allergan received FDA approval for its Juvederm gel family of facial wrinkle fillers; and Trubion filed for its IPO. The Centient Biotech 200™ was down a huge 2.78%, falling 104 points to 3652.64, the first triple digit loss in 2006. More details...
